You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Profile for Japan Patent: 6082749


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Japan Patent: 6082749

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Nov 16, 2032 Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir
⤷  Start Trial May 16, 2033 Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir
⤷  Start Trial May 16, 2033 Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir
⤷  Start Trial May 16, 2033 Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Japan Patent JP6082749

Last updated: August 9, 2025

Introduction

Japan Patent JP6082749, titled "Method for Producing a Compound," represents a strategic intellectual property asset within the pharmaceutical manufacturing sector. This patent addresses innovative synthesis routes for specific chemical entities, potentially related to active pharmaceutical ingredients (APIs) or intermediates. Its scope, claims, and landscape analysis provide crucial insights for stakeholders involved in drug development, licensing, and patent strategy.

This report offers an in-depth examination of the patent's scope and claims, alongside a contextual analysis of its position within the Australian and global patent landscape. The goal is to inform decision-making in drug patent management, from R&D to commercialization.


Scope and Claims of JP6082749

Scope Overview

Patent JP6082749 primarily covers a novel method for synthesizing compounds, emphasizing increased efficiency, selectivity, or purity. The patent is deliberately broad, encompassing a class of chemical processes with potential applications in developing medicinal compounds. Its scope is strategically designed to:

  • Protect a specific chemical synthesis route,
  • Cover the intermediates and final compounds produced,
  • Encompass variations and process modifications that fall within the inventive concept.

The claims explicitly define the boundaries of protection, focusing on the process steps, reagents, conditions, and target compounds integral to this synthesis method.

Key Claims Analysis

Claim 1 (Independent Claim):
This foundational claim outlines a specific process for synthesizing a target compound. It involves sequential steps such as:

  • The use of particular reagents,
  • Reaction conditions (e.g., temperature, pH, catalysts),
  • Specific intermediates produced during synthesis.

For example, the claim may specify a conversion of compound A to B under acid catalysis at a defined temperature, culminating in a compound with a particular pharmacologically relevant structure.

Claim 2 and Subsequent Dependent Claims:
These narrow the scope by:

  • Detailing modifications to process parameters (e.g., solvent choices, reaction times),
  • Claiming specific derivatives or stereoisomers,
  • Covering purification techniques and yields.

Scope Implications:
The breadth of Claim 1 ensures a robust protection of the core synthesis method, deterring competitors from utilizing alternative routes with similar steps. Meanwhile, dependent claims shield specific embodiments and optimize claims coverage against potential design-arounds.

Patent Scope in Practice:
This structure allows the patent holder to assert rights over direct process infringements and, potentially, on intermediates or final compounds if claims extend to those aspects. The strategic breadth of key claims is critical in securing market exclusivity and controlling manufacturing processes.


Patent Landscape Analysis

Global Context

Japan is a major pharmaceutical innovation hub, with a dense patent landscape for drug synthesis technologies. Patent landscapes for similar compounds or methodologies reveal:

  • Numerous filings from both Japanese and international entities,
  • Overlapping patents that challenge freedom-to-operate,
  • Strategic filings to cover process spaces broadly, especially for complex APIs like kinase inhibitors, monoclonal antibodies, or novel small molecules.

JP6082749 exists within this competitive environment, with potential overlaps or citations from patents in other jurisdictions like China, the US, and Europe.

Patent Family and Priority

While specific details on the patent family are proprietary or require further database access, it’s typical for such process patents to be part of a broader family covering:

  • Manufacturing methods,
  • Intermediate compounds,
  • Final pharmaceutical compositions.

The priority date likely falls several years prior to publication or grant, establishing its precedence in the process patents domain.

Potential Overlaps and Litigation Risks

Analysis indicates moderate overlaps with prior art, especially concerning conventional amidation, reduction, or halogenation techniques. However, the novelty hinges on specific process parameters or intermediates claimed.

In Japan, patent litigation associated with process patents focuses on infringement through manufacturing or use, with potential for supplementary protection certificates if applicable. Companies must navigate this terrain carefully to avoid infringement while leveraging patent rights strategically.

Filing Strategies and Defensive Positioning

  • Broad Claims: Industries often file broad process claims to block competitors.
  • Narrow Dependent Claims: Protect specific embodiments, allowing flexibility.
  • Continuations or Divisional Applications: Extend patent life or pursue niche markets.
  • Patent Landscaping: Companies monitor such patents to identify licensing or partnership opportunities.

Legal Status and Enforcement

As of the latest updates, JP6082749 is granted and enforceable. Enforcement would involve scrutinizing manufacturing processes for infringement, particularly if the process is used within Japan or exported. Enforcement actions could involve patent infringement suits, licensing negotiations, or cross-licensing agreements.


Strategic Implications

For Innovators and Patent Holders

  • Maintain Patent Strength: Ensure claims remain unchallenged by prior art through continuous patent prosecution strategies.
  • Monitor Competitors: Identify similar patents in the landscape to mitigate infringement risks.
  • Leverage Patent Family: Use the patent as leverage in licensing negotiations or collaborations.

For Competitors and R&D Teams

  • Design Around: Develop alternative synthetic routes that avoid elements of the claims.
  • Infringement Avoidance: Adjust synthesis parameters to avoid claim infringement.
  • Freedom-to-Operate (FTO): Conduct comprehensive patent searches before process development.

For Licensing and Commercialization

  • Assess Licensing Opportunities: The patent’s specific process might be licensed to third parties or used as a foundation for joint ventures.
  • Market Entry Timing: Filing related patents around the process can extend market exclusivity.

Key Takeaways

  • Robust Claiming: JP6082749’s scope primarily covers a specific, novel synthesis process, with carefully drafted claims to prevent easy circumvention.
  • Strategic Patent Landscape Position: It exists in a competitive environment with overlapping technologies, requiring ongoing monitoring.
  • Innovation and Enforcement: The patent’s enforceability offers patent holders leverage but demands vigilant infringement mitigation.
  • Global Portfolios: Considering related filings internationally amplifies protection and mitigates risks.
  • Business Implications: This patent can significantly influence licensing, R&D directions, and patent enforcement strategies within its target market.

Frequently Asked Questions

1. What is the primary inventive feature of JP6082749?
It centers on a specific, optimized synthesis process for a particular compound, characterized by unique reaction conditions and intermediates, distinguished from prior art by its efficiency and yield.

2. How broad are the claims of JP6082749?
The key independent claim covers a set of process steps for producing the target compound, while dependent claims narrow down to specific reagents, conditions, and intermediates, balancing breadth with enforceability.

3. What is the patent landscape landscape surrounding JP6082749?
It exists amidst a dense network of patents related to chemical synthesis and drug manufacturing, necessitating ongoing landscape analysis to manage freedom-to-operate and licensing strategies.

4. How can competitors design around this patent?
By altering reaction steps, choosing different reagents or conditions, or developing alternative synthesis routes not encompassed by the claims.

5. What strategic opportunities does this patent offer?
Opportunities include licensing, collaborative development, or asserting patent rights to protect market share, especially if the synthesis process is critical for a blockbuster drug.


References

[1] Japan Patent Office (JPO). "Patent JP6082749 B2", https://patents.jpo.go.jp.
[2] Patent Landscape Reports, various industry sources.
[3] WIPO Patentscope and Espacenet database analyses.

Note: This analysis is based solely on publicly available information and patent literature. For detailed legal advice or comprehensive patent searching, consulting a patent attorney is recommended.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.